WeAreDiabetic.org - The Social Support Network for People Living with Diabetes and Pre-Diabetes

InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting

LOS ALTOS, Calif., May 28 /PRNewswire/ --
InteKrin Therapeutics, Inc. announced today it will present Phase 2a
clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the
American Diabetes Association annual meeting in New Orleans Saturday,
June 6, 2009 during the "Novel Diabetes Therapies in Development in
Humans" session at 4:00 pm CDT.

Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics,
will provide a summary of the latest clinical data supporting the
design of INT131 to safely and effectively address insulin resistance
in a presentation entitled "INT131: Significantly Lowers Glucose
Without Typical Thiazolidinedione (TZD) Side Effects in Patients with
Type 2 Diabetes."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b
testing that addresses insulin resistance, a key etiological feature in
the onset and subsequent progression of type 2 diabetes. Purposefully
designed as a SPPARM, INT131 selectively modulates PPAR-gamma, thereby
allowing the retention of the clinically proven anti-diabetic efficacy
of PPAR gamma activation, while mitigating or eliminating the well
recognized side effects of TZD full PPAR gamma agonists rosiglitazone
and pioglitazone (Avandia(R) and Actos(R) respectively).

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug
development company focused on diabetes, obesity and metabolic disease.
InteKrin's business strategy is to build a robust portfolio of high
value products by in-licensing clinical-stage therapeutic candidates
that address significant unmet medical needs and rapidly move them
through critical development stages. InteKrin's team of world-class
scientific and medical experts includes veterans from several
successful BioPharma organizations, internationally recognized experts
in nuclear receptors and metabolism, top scientists formerly with the
Food and Drug Administration and key clinical and commercialization
leaders.